TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06565442

Intervention type: DEVICE
Intervention: NeuraSignal transcranial doppler robot
Description: measure cerebral blood flow correlated with arterial blood pressure to generate individualized cerebral autoregulatory curves
Study: NCT05627258

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB0115-00-AB
Description: VRC01.23LS is a broadly neutralizing monoclonal antibody that targets the CD4 binding site in the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB0115-00-AB
Description: VRC01.23LS is a broadly neutralizing monoclonal antibody that targets the CD4 binding site in the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB0115-00-AB
Description: VRC01.23LS is a broadly neutralizing monoclonal antibody that targets the CD4 binding site in the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB0115-00-AB
Description: VRC01.23LS is a broadly neutralizing monoclonal antibody that targets the CD4 binding site in the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB0115-00-AB
Description: VRC01.23LS is a broadly neutralizing monoclonal antibody that targets the CD4 binding site in the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB0115-00-AB
Description: VRC01.23LS is a broadly neutralizing monoclonal antibody that targets the CD4 binding site in the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.
Study: NCT04801225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive electromagnetic stimulation for acute stroke treatment
Description: Bilateral electromagnetic stimulation to improve blood flow in ischemic regions of acute stroke as an adjunct to current standard-of-care
Study: NCT06643377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide
Description: Oral tablet
Study: NCT06392919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS intervention timing: rTMS is applied after the tracheal tube is removed in the PACU. Stimulation site: DLPFC (left dorsolateral prefrontal cortex); Stimulation intensity: 100% RMT; Stimulation frequency: 10Hz; Total number of stimulation pulses: 2000. Pulse characteristics: Each duration lasts 5 seconds, with a 25-second interval.
Study: NCT06576765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0780
Description: Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0780
Description: Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0780
Description: Dose 1
Study: NCT04532047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldurazyme (laronidase)
Description: Enzyme replacement therapy for lysosomal storage diseases
Study: NCT06058377

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo optional collection of tissue and/or blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo optional collection of tissue and/or blood

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Undergo MammaPrint testing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mammography
Description: Undergo mammography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mammography
Description: Undergo mammography

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06066138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab administered via IV at either 1,200 mg q3 weeks, or 1,680 mg q4 weeks for the first 2 doses followed by 840mg q2 weeks or q6 weeks.
Study: NCT05578300

Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombus analyses
Description: Physical, histology, biochemical or protein expressions of the thrombi obtained from thrombectomy procedures may contain information regarding the etiology of stroke and relevant disease pathology. The investigators shall store the thrombus, if any, yielded from thrombectomy procedures for future analyses.

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging assessment
Description: All imaging data will be deidentified before assessment. Plain computer tomography of the brain (CT brain), CT angiography (CTA), CT perfusion (CTP), magnetic resonance imaging of the brain (MRI), digital subtraction imaging (DSA) will be analysed. The investigators shall blind the assessors from treatment choice and outcome in all analyses that require human assessment.
Study: NCT05932485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate nerve block
Description: Before the operation, the left stellate ganglion block was performed, and 0.375% ropivacaine 5ml was injected into the stellate ganglion.
Study: NCT05523869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal topotecan
Description: Patients meeting all inclusion criteria and not meeting exclusion criteria will be assigned to receive pars plana vitrectomy with or without scleral buckle with intravitreal topotecan 8 µg/0.1mL, administered preoperatively within one week from surgery, intraoperatively during surgery, as well as postoperatively at 2 weeks, 4 weeks, 8 weeks, 12 weeks and 16 weeks, for a total of 7 injections.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with or without scleral buckle
Description: Standard three-port pars plana vitrectomy with or without scleral buckle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy with or without scleral buckle
Description: Standard three-port pars plana vitrectomy with or without scleral buckle.
Study: NCT06081738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: a combination of 0.04 mg/kg neostigmine with 0.01 mg/kg atropine intravenously at the reappearance of a second twitch of TOF after the last dose of rocuronium
Study: NCT04972682

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsy
Description: Laparoscopic total hysterectomy, bilateral salpingo-oophorectomy (BSO), and sentinel lymph node (SLN) biopsy are executed by 1 of 5 experienced gynecologic oncologists. SLN mapping utilizes indocyanine green (ICG) at a standard concentration of 2.5 mg/mL - 1 mL is injected into the cervix at the 3 and 9 o'clock positions (total dose - 5 mg) to a depth of 5-10 mm, initiated right after general anesthesia induction. Diagnostic laparoscopy employs the Image 1S equipment (KARL STORZ©, Tuttlingen, Germany). Upon examination, fluorescence in the near-infrared spectrum is observed. Successful mapping is indicated by identifying a lymphatic vessel with at least one LN. Detected SLNs are then extracted, and the total hysterectomy with BSO is completed. SLN frozen section remains at the surgeon's discretion. If metastasis surfaces in the SLN either during the frozen section or routine assessment, the option for systematic LN dissection in a subsequent procedure exists although not mandatory.
Study: NCT05058690

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test
Description: * Obtain blood sample for glucose assessment (time 0 sample). This may be obtained via venepuncture or after cannula insertion.~* Test a small sample using a near patient glucose testing meter. If the result on the glucose meter is greater than or equal to 11mmol/L, send the blood sample urgently to lab. If it is confirmed by biochemistry to be above 11mmol/L, there is no need to continue test.~* If the result is less than 11mmol/L on meter, give the patient the glucose solution to drink.~* Collect a further blood sample at 120 minutes.~* Send samples all together to laboratory for glucose measurement.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test
Description: * Obtain blood sample for glucose assessment (time 0 sample). This may be obtained via venepuncture or after cannula insertion.~* Test a small sample using a near patient glucose testing meter. If the result on the glucose meter is greater than or equal to 11mmol/L, send the blood sample urgently to lab. If it is confirmed by biochemistry to be above 11mmol/L, there is no need to continue test.~* If the result is less than 11mmol/L on meter, give the patient the glucose solution to drink.~* Collect a further blood sample at 120 minutes.~* Send samples all together to laboratory for glucose measurement.
Study: NCT06081738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: 2-4 mg/kg sugammadex intravenously upon the reappearance of a post-tetanic count 1-2 or a second twitch of TOF after the last dose of rocuronium
Study: NCT05481905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENX-101
Description: Adjunctive treatment to current antiseizure medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENX-101
Description: Adjunctive treatment to current antiseizure medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ENX-101
Description: Adjunctive treatment to current antiseizure medication
Study: NCT06100848

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Microbiological analysis after Caries treatment
Description: Microbiological analysis was conducted for 30 patients using 30 microbiological plates. These plates were opened simultaneously with the start of the treatment and closed 40 minutes later.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Microbiological analysis after Caries treatment and fumigation
Description: Microbiological analysis was conducted for 30 patients using 30 microbiological plates. These plates were opened simultaneously with the start of the treatment and closed 60 minutes later (when fumigation was finished)
Study: NCT05554328

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study: NCT06303375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesiotaping using inhibition technique in tight muscles and facilitation technique in weak muscles for LCS. Treatment sessions 3 days per week for almost 04 weeks.~10 mins moist hot pack~* Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.~* Strengthening of weak abdominals and gluteal muscles 2-3 times in a week
Study: NCT05554328

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tumor biopsy
Study: NCT06303375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: 10 mins moist hot pack~* Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.~* Strengthening of weak abdominals and gluteal muscles 2-3 times in a week
Study: NCT05554328

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration or biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration or biopsy
Study: NCT06303375

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: 10 mins moist hot pack~* Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.~* Strengthening of weak abdominals and gluteal muscles 2-3 times in a week
Study: NCT05554328

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selumetinib Sulfate
Description: Given PO
Study: NCT06378528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 3 Intravenous ketamine administrations (0.5mg/kg, not to exceed 40mg dose) immediately prior to a psychotherapy session over the span of 6 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartSleep EEG recording headband
Description: Participants will complete 7 nights of at-home sleep recordings for exploratory analysis
Study: NCT06577454

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS (MagVenture MagPro 100 with MagOption)
Description: TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-8 TMS coil.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS (MagVenture MagPro 100 with MagOption)
Description: TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-8 TMS coil.
Study: NCT06427798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE
Description: 68Ga-DOTATATE PET/CT whole-body scanning will be done at target dose of 5 mCi. The whole-body PET/CT scan will be started approximately 60 minutes after the tracer injection and will take up to 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE
Description: 68Ga-DOTATATE PET/CT whole-body scanning will be done at target dose of 5 mCi. The whole-body PET/CT scan will be started approximately 60 minutes after the tracer injection and will take up to 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE
Description: 68Ga-DOTATATE PET/CT whole-body scanning will be done at target dose of 5 mCi. The whole-body PET/CT scan will be started approximately 60 minutes after the tracer injection and will take up to 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [203Pb]VMT-alpha-NET
Description: \[203Pb\]VMT-alpha-NET (6 mCi) will be given IV at 7 days prior.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [212Pb]VMT-alpha-NET
Description: \[212Pb\]VMT-alpha-NET will be given IV on Day 1 of every cycle for 4 cycles total at escalating doses in Phase I and at MTD during Phase II. One cycle is 8 weeks.
Study: NCT06349083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: One 25 mg capsule and one 5 mg capsule (30 mg total) administered once orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Placebo
Description: Two matching placebo capsules administered once orally

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive therapy sessions
Description: Participants will receive three supportive therapy sessions of manual-based treatment from a Center for Psychedelic Medicine (CPM) clinician, accompanied by a Silver Hill Hospital (SHH) therapist who has an ongoing therapeutic relationship with the participant. The CPM clinician will be a licensed physician, clinical psychologist, or nurse practitioner who will be solely responsible for the content of the intervention. The SHH therapist will provide additional support and continuity with clinical treatment.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive therapy sessions
Description: Participants will receive three supportive therapy sessions of manual-based treatment from a Center for Psychedelic Medicine (CPM) clinician, accompanied by a Silver Hill Hospital (SHH) therapist who has an ongoing therapeutic relationship with the participant. The CPM clinician will be a licensed physician, clinical psychologist, or nurse practitioner who will be solely responsible for the content of the intervention. The SHH therapist will provide additional support and continuity with clinical treatment.
Study: NCT05309200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCE-205
Description: The drug product, OCE-205, is a sterile solution to be used for intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCE-205
Description: The drug product, OCE-205, is a sterile solution to be used for intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCE-205
Description: The drug product, OCE-205, is a sterile solution to be used for intravenous infusion.
Study: NCT05331274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise group
Description: 1 stage~* In a sitting position, pull the leg up and extend the knee forward~* Standing, bending forward and bending the knee~* Supine, tucked legs~* Maintaining spinal smoothness in crawling~* Prone heel pull to buttock~Stage 2~* Prone on forearms-hands~* Extending the supine hands to the knees~* Rounding and hollowing the waist in crawling~* Progressive sit-stand~* Standing up from sitting and putting on and taking off socks~* Reaching up while standing and maintaining the straightness of the spine~* Squatting~* Climbing and descending stairs~Stage 3~* Maintaining standing, arms forward~* Slipping hands on the bed while standing~* Initiating the standing throw and maintaining the position until the final interval~* Putting on and taking off socks while standing~* Taking weight towards the ground from a certain height~* Picking up different weights from the ground~* Push-pull items~* Crossing obstacles of certain height~* Walking a certain distance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pain training group
Description: The training provides participants with the opportunity to explain the central sensitization mechanism and also integrates the behavioral, psychological and environmental aspects that contribute to the persistence of pain. It is intended to teach that education reduces pain and improves endogenous pain inhibition, mental health, physical function, vitality and self-rated disability in patients with chronic pain, and reduces passive coping, kinesiophobia, and catastrophizing.~The same exercises will be applied as the exercise group.
Study: NCT06285981

Intervention type: DEVICE
Intervention: Chimaera Long Nail
Description: The CHIMAERATM, is an internal fixation system intended intended for insertion into the medullary canal of a femur in individuals suffering from stable and unstable pertrochanteric, intertrochanteric and subtrochanteric fractures of the femur alone or when these fractures occur in combination with shaft fractures extending distally to a point approximately 10cm proximal to the intercondylar notch.
Study: NCT05894304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suspension system
Description: suspended from the handles of the straps by either their hands or feet while the non-suspended pair of extremities are in contact with the ground leading to muscle activation due to unstable base of support
Study: NCT06427798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [212Pb]VMT-alpha-NET
Description: \[212Pb\]VMT-alpha-NET will be given IV on Day 1 of every cycle for 4 cycles total at escalating doses in Phase I and at MTD during Phase II. One cycle is 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [212Pb]VMT-alpha-NET
Description: \[212Pb\]VMT-alpha-NET will be given IV on Day 1 of every cycle for 4 cycles total at escalating doses in Phase I and at MTD during Phase II. One cycle is 8 weeks.
Study: NCT06575192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARTIA Reconstructive Tissue Matrix
Description: Surgical Implant
Study: NCT05894304

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scapular training exercises
Description: Scapular muscle strength by resistance
Study: NCT06115473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine
Description: patients will receive epinephrine prepared as 10 ml syringe filled with 10 ml of epinephrine 10 mcg/ml. prepared by drawing 1ml epinephrine 1mg ampule into 9 ml saline then discarding 9 ml and adding another 9 ml saline. now the investigators have 10 ml of epinephrine 10 mcg/ ml (1:100,000), then 10 µg will be given intravenously every 2-minute starting before intubation and continue during and after intubation for 4 times or until the systolic blood pressure (SBP) will be at least 90 mmHg or the mean arterial pressure (MAP) 65 mmHg or greater or after 4th dose of epinephrine and still hypotensive vasopressor (norepinephrine 30 ng /kg/min.) will be added or increased.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic fluid
Description: patients will receive IV bolus isotonic fluid 500 ml